Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Mar 6;12(3):322-325.
doi: 10.1093/ckj/sfz019. eCollection 2019 Jun.

Sodium-glucose cotransporter inhibitors: beyond glycaemic control

Ander Vergara  1   2 , Conxita Jacobs-Cachá  1   2 , María José Soler  1   2
Affiliations

Sodium-glucose cotransporter inhibitors: beyond glycaemic control

Ander Vergara et al. Clin Kidney J. .

Abstract

Diabetes increases the risk of adverse cardiovascular and renal events. Recently, sodium-glucose co-transporter 2 (SGLT2) inhibitors have been demonstrated to reduce cardiovascular complications and slow diabetic kidney disease progression in patients with type 2 diabetes. The glycaemic control exerted by these drugs is not greater than the one achieved with other classical glucose-lowering medications such as sulphonylureas. For that reason, plausible renoprotective mechanisms independent from glycaemic control have been proposed such as blood pressure control, body weight loss, intraglomerular pressure reduction and a decrease in urinary proximal tubular injury biomarkers. Interestingly, the hypothesis that SGLT2 inhibitors have a direct renoprotective effect has been addressed in diabetic and non-diabetic models. In this editorial, we update the different postulated mechanisms involved in the cardiorenal protection afforded by SGLT2 inhibition in chronic kidney disease.

Keywords: SGLT2; chronic kidney disease; diabetic nephropathy; type 2 diabetes.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
Suggested mechanisms for cardiorenal protection with SGLT2 inhibition.
See this image and copyright information in PMC

References

    1. Xie Y, Bowe B, Mokdad AH. et al. Analysis of the Global Burden of Disease study highlights the global, regional, and national trends of chronic kidney disease epidemiology from 1990 to 2016. Kidney Int 2018; 94: 567–581 - PubMed
    1. Patel A, MacMahon S, Chalmers J. et al.; ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560–2572 - PubMed
    1. Palazzolo G, Albanese NN, DI Cara G. et al. Proteomic analysis of exosome-like vesicles derived from breast cancer cells. Anticancer Res 2012; 32: 847–860 - PubMed
    1. Gerstein HC, Miller ME, Byington RP. et al.; Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545–2559 - PMC - PubMed
    1. UPDS Group (UKPDS). Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 837–853 - PubMed